ArticleInternational journal of peptide research and therapeutics2022
Design of an Epitope-Based Peptide Vaccine Against Dengue Virus Isolate from Eastern Uttar Pradesh, India.
Article in International journal of peptide research and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Designing potent and immunogenic epitope based peptide vaccine against all serotypes of DENV via structural, physico-chemical and immunoinformatics-based approaches.Scientific reports · 2026Article
- Current status of the development of dengue vaccines.Vaccine: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue outbreaks are a serious public health concern that occurs on a regular basis in various locations of India. According to the Government of India's National Center for Vector-Borne Disease Control, a total of 1,23,106 dengue cases were identified in India as of October 2021. The currently available dengue vaccine was found to be ineffective against all serotypes of the virus. Dengue virus serotype 2 was reported to be the sole predominant serotype in Eastern Uttar Pradesh, India. An epitope-based peptide vaccine is believed to be safe and effective against all serotypes of the dengue virus. In this work, an epitope-based peptide vaccine based on envelope protein against the dengue virus was developed using the reverse vaccinology method. T-cell epitopes present in the envelope protein were screened using different immunoinformatic tools. Epitopes predicted by all servers were chosen and additionally picked out on the grounds of their antigenic reactivity, immunogenicity, toxicity, and allergenicity assessment. Three potent T cell epitopes as IVQPENLEY, ILIGVVITW, and DTAWDFGSL were screened, which binds with HLA-B*35:01, HLA-B*58:01, HLA-A*26:01 alleles, respectively. To build a 3D structure model of epitopes and alleles, the PepstrMod and Swiss-Model servers were used. Predicted epitopes and HLA alleles were docked using the HPEPDOCK server to confirm binding ability. These anticipated epitopes were found to cover the greatest number of populations in India and around the world. These identified epitopes have a high potential for eliciting an immune response in the development of a vaccine against the dengue virus, while further experimental validation is required for final confirmation. Supplementary Information: The online version contains supplementary material available at 10.1007/s10989-022-10402-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.